Drug Trial Radar · NCT07123727
A Study to Examine Anktiva for the Treatment of COVID-19.
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 4, 2025
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
Conditions
- Long COVID
- Long COVID Syndrome
- Long Covid 19
Interventions
AnktivaDrug
600ug of NAI administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
- Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
- Incidence of serious adverse events (SAEs) through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
- Incidence of abnormal changes in safety laboratory tests (CBC and CMP).Time frame: Through the end of the study treatment period (approximately 75 days).
- Clinically important changes in vital signs such as temperature in degrees Fahrenheit.Time frame: Through the end of the study treatment period (approximately 75 days).
- Clinically important changes in vital signs such as heart rate in beats per minute.Time frame: Through the end of the study treatment period (approximately 75 days).
- Clinically important changes in vital signs such as blood pressure in millimeters of mercury (mmHg).Time frame: Through the end of the study treatment period (approximately 75 days).
- Clinically important changes in vital signs such as respiratory rate in breaths per minute.Time frame: Through the end of the study treatment period (approximately 75 days).
- Clinically important changes in vital signs such as oxygen saturation in percentage.Time frame: Through the end of the study treatment period (approximately 75 days).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chan Soon-Schiong Institute for Medicine (CSSIFM)
El Segundo, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.